Recombinant DNA. The Grantee and Sponsoring Institution acknowledge that the statement in the Application to LLS, concerning recombinant DNA and the safeguards to be employed, are accurate descriptions of the circumstances pertaining to this aspect of the research proposed in the Application to LLS. Projects which do not involve recombinant DNA must so state. Failure to notify LLS of non- compliance with these guidelines on the use of recombinant DNA will result in suspension or termination of this Grant.
Recombinant DNA. By signing the award or accepting funds under the award, you assure that all work involving the use of recombinant DNA will be in compliance with guidance provided at xxxxx://xxx.xx.xxx.xxx/biotechnology/biosafety-and- recombinant-dna-activities/
Recombinant DNA. For all research involving recombinant DNA techniques, the CWRU agrees to meet the requirements of the NIH Guidelines for Research Involving Recombinant DNA Molecules (the Guidelines) (59 FR 34496, July 5, 1994 or latest revision).
Recombinant DNA. For all research involving recombinant DNA techniques, the SUBCONTRACTOR agrees to meet the requirements of the NIH Guidelines for Research Involving Recombinant DNA Molecules (the Guidelines) (59 FR 34496, July 5, 1994 or latest revision).
Recombinant DNA. SCOR Director and Sponsoring Institution acknowledge that the statement in the Application concerning recombinant DNA and the safeguards to be employed is an accurate description of the circumstances pertaining to this aspect of the research proposed in the Application. Projects which do not involve recombinant DNA must so state. Failure to notify LLS of non- compliance with these guidelines on the use of recombinant DNA will result in suspension or termination of this Agreement.
Recombinant DNA. The Consultant agrees to abide by the current HHS Guidelines for Research involving Recombinant DNA Molecules. All research involving recombinant DNA techniques that is supported by the Public Health Service must meet the requirements of these Guidelines, which were developed in response to the concerns of the scientific and lay communities about the possible effects of recombinant DNA research. Their purpose is to specify practices for the construction and handling of recombinant DNA molecules and organisms or viruses containing recombinant DNA. As defined by the Guidelines, "recombinant DNA" corresponds to: (1) molecules that are constructed outside living cells by joining natural or synthetic DNA segments to DNA molecules that canreplicate in a living cell; or (2) DNA molecules that result from the replication of a molecule described in (1). Several types of studies involving recombinant DNA are exempt from the Guidelines while others are prohibited by the Guidelines. For the remainder, the Consultant must establish and implement policies that provide for the safe conduct of the research in full conformity with the Guidelines. This responsibility includes establishing an institutional biosafety committee to review all recombinant DNA research to be conducted at or sponsored by the Consultant and to approve those projects that are in conformity with the Guidelines. For each approved project, a valid Memorandum of Understanding and Agreement (MUA) shall be prepared for submission when solicited by an appropriate HHS staff member. The MUA is considered approved after review and acceptance by XXXX and by the Consultant.
Recombinant DNA. The Grantee and Sponsoring Institution acknowledge that the statement in the Application to LLS, concerning recombinant DNA and the safeguards to be employed are accurate descriptions of the circumstances pertaining to this aspect of the research proposed in the Application to LLS. Projects which do not involve recombinant DNA must so state. Failure to notify LLS of non- compliance with these guidelines on the use of recombinant DNA may result in suspension or termination of this Grant. If the Grant is terminated, any unused Grant funds and/or funds paid after the noncompliance occurs must be returned to LLS immediately.
